Home Newsfeeds Guggenheim Downgrades Rubius Therapeutics to Neutral

Guggenheim Downgrades Rubius Therapeutics to Neutral

Guggenheim analyst Michael Schmidt downgrades Rubius Therapeutics (NASDAQ:RUBY) from Buy to Neutral.

byBenzinga Newsdesk

September 13, 2022

1 minute read

Guggenheim analyst Michael Schmidt downgrades Rubius Therapeutics (NASDAQ:RUBY) from Buy to Neutral.

Analyst Ratings

Expert Ratings for Trade Desk

By Benzinga Insights

June 2, 8:02 AM

Within the last quarter, Trade Desk (NASDAQ:TTD) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

TTD

Leslies Q3 Adj. EPS $0.68 Misses $0.74 Estimate, Sales $673.60M Miss $691.60M Estimate

By Bill Haddad

August 5, 7:07 AM

Leslies (NASDAQ:LESL) reported quarterly earnings of $0.68 per share which missed the analyst consensus estimate of $0.74 by 8.11 percent. This is a 6.25 percent increase over earnings of $0.64 per share from the same

LESL

$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,900 Today

By Benzinga Insights

November 9, 4:41 PM

Pioneer Natural Resources (NYSE:PXD) has outperformed the market over the past 15 years by 4.7% on an annualized basis producing an average annual return of 11.22%. Currently, Pioneer Natural Resources has a market capitalization of $58.12 billion.

PXD

FDA Approves Rivfloza For Children ≥9 Years Old And Adults Living With Primary Hyperoxaluria Type 1 (PH1), A Rare Genetic Condition

By Benzinga Newsdesk

October 2, 11:16 AM

Novo Nordisk announced today that the U.S. Food and Drug Administration (FDA) has approved RivflozaTM (nedosiran) injection 80 mg, 128 mg, or 160 mg, a once-monthly subcutaneous ribonucleic acid interference (RNAi)

NVO

Guggenheim Downgrades Rubius Therapeutics to Neutral

Related Posts

Expert Ratings for Trade Desk

Leslies Q3 Adj. EPS $0.68 Misses $0.74 Estimate, Sales $673.60M Miss $691.60M Estimate

$1000 Invested In This Stock 15 Years Ago Would Be Worth $4,900 Today

FDA Approves Rivfloza For Children ≥9 Years Old And Adults Living With Primary Hyperoxaluria Type 1 (PH1), A Rare Genetic Condition